Shares of DarioHealth Corp. (NASDAQ:DRIO – Get Rating) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the last year is $17.44.
Several brokerages recently commented on DRIO. Alliance Global Partners raised shares of DarioHealth from a “neutral” rating to a “buy” rating and set a $8.75 price objective for the company in a research note on Friday, May 13th. Cowen upped their price target on shares of DarioHealth to $18.00 and gave the stock a “na” rating in a report on Monday. Aegis cut their price objective on DarioHealth from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, January 26th. Finally, Cowen upped their target price on DarioHealth from $14.00 to $18.00 in a report on Monday.
Several institutional investors have recently modified their holdings of the stock. Morgan Stanley raised its position in DarioHealth by 219.2% during the 1st quarter. Morgan Stanley now owns 3,543 shares of the company’s stock worth $68,000 after purchasing an additional 2,433 shares during the last quarter. UBS Group AG increased its stake in shares of DarioHealth by 706.5% in the third quarter. UBS Group AG now owns 4,250 shares of the company’s stock valued at $58,000 after buying an additional 3,723 shares during the period. Steward Partners Investment Advisory LLC bought a new position in shares of DarioHealth during the first quarter worth about $25,000. Focused Wealth Management Inc boosted its holdings in DarioHealth by 150,000.0% in the fourth quarter. Focused Wealth Management Inc now owns 6,004 shares of the company’s stock valued at $78,000 after acquiring an additional 6,000 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in DarioHealth by 1,498.4% in the fourth quarter. Wells Fargo & Company MN now owns 7,992 shares of the company’s stock valued at $103,000 after acquiring an additional 7,492 shares during the last quarter. 49.01% of the stock is currently owned by institutional investors.
DarioHealth (NASDAQ:DRIO – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.22. DarioHealth had a negative return on equity of 73.61% and a negative net margin of 311.13%. During the same quarter in the prior year, the business earned ($0.92) earnings per share. As a group, research analysts forecast that DarioHealth will post -3.17 EPS for the current year.
DarioHealth Company Profile (Get Rating)
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems.
- Get a free copy of the StockNews.com research report on DarioHealth (DRIO)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.